Accession Number : AD1050402


Title :   Epigenetic Machinery Regulates Alternative Splicing of Androgen Receptor (AR) Gene in Castration-Resistant Prostate Cancer (CRPC)


Descriptive Note : Technical Report


Corporate Author : University of Texas Southwestern Medical Center Dallas United States


Personal Author(s) : Hsieh , Jer-Tsong


Full Text : http://www.dtic.mil/dtic/tr/fulltext/u2/1050402.pdf


Report Date : 01 Sep 2017


Pagination or Media Count : 10


Abstract : Conventional chemotherapy with cell killing en mass often targets mitotic cells with less specificity, which likely leads toundesirable side effect. Knowing specific molecular defects in cancer cells has led to discover new chemotherapeutic agents.Thus, combined agents targeting different defected pathways in cancer cells have a better chance to eradicate tumorcompletely. Thus, to achieve a cure, a comprehensive targeting strategy needs to be implemented. In addition, improvedmethods for monitoring drug delivery and tumor response in a nearly real-time manner should offer a safe and effectivetreatment. This project carried out by a team of chemist, radiologist, and molecular tumor biologist is to develop a novel drugdelivery system with new small molecular therapeutic agents assisted with new imaging probe is expect to bring a new frontierfor prostate cancer (PCa) management. Our objective is to develop dendrimer-based theranostic agent with prostate cancerspecificity and positron emission tomography imaging capability that can prevent the early onset of PCa metastasis or delaythe progression of metastasis. The mission of my project is to design small peptide derived from tumor suppressor DAB2family as therapeutic agent and examine its biology activities.


Descriptors :   culture techniques , drug resistance , positron emission tomography , positron emissions , cell line , department of defense , drug therapy , biomedical research , castration , chemotherapeutic agents , chemotherapy , inhibitors , molecules , androgens , cancer , neoplasms , prostate , therapy , prostate cancer , medical personnel


Distribution Statement : APPROVED FOR PUBLIC RELEASE